As of June 23, 2025, Ascendis Pharma A/S (ASND) reports a EV/EBITDA of -30.41.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Ascendis Pharma A/S's EV/EBITDA to Peers
To better understand Ascendis Pharma A/S's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Ascendis Pharma A/S (ASND) | -30.41 |
| TG Therapeutics Inc (TGTX) | 82.81 |
| Genmab A/S (GMAB.CO) | 33.75 |
| Halozyme Therapeutics Inc (HALO) | 10.45 |
| Bavarian Nordic A/S (BAVA.CO) | 6.81 |
| Saniona AB (SANION.ST) | 4.25 |
Compared to its competitors, Ascendis Pharma A/S's EV/EBITDA is among the lowest compared to peers, which may indicate undervaluation or market concerns about future performance.